Study | Location | Treatment groups | Followup, months | Number of patients | Age, years |
---|---|---|---|---|---|
VISION 2004 [6] | United States, Canada, Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, UK, Brazil, Chile, Colombia, and Australia | Pegatanib and photocoagulation | 12 | 904/304a | 75/77a |
ANCHOR 2006 [9] | United States, France, Germany, Hungary, Czech Republic, and Australia | Ranibizumab and photocoagulation | 24 | 280/143b | 76.7/77.8b |
MARINA 2006 [10] | United States | Ranibizumab and photocoagulation | 24 | 478/238b | 77/77b |
PIER 2008 [36] | United States | Ranibizumab and photocoagulation | 24 | 121/63b | 79/78b |
ABC 2010 [34] | United Kingdom | Bevacizumab and photocoagulation | 12 | 65/66c | 79/81c |
SACU 2009 [37] | Austria | Bevacizumab and photocoagulation | 12 | 14/14c | 78/78c |
CATT 2011 [12] | United States | Bevacizumab and ranibizumab | 24 | 586/599d | 79.7/78.8d |
IVAN 2013 [14] | United Kingdom | Bevacizumab and ranibizumab | 24 | 296/314d | 77.8/77.7d |
GEFAL 2013 [35] | France | Bevacizumab and ranibizumab | 12 | 191/183d | 79.6/78.7d |
MANTA 2013 [16] | Austria | Bevacizumab and ranibizumab | 12 | 154/163d | 76.7/77.6d |
Subramanian 2010 [38] | United States | Bevacizumab and ranibizumab | 12 | 15/7d | 78/80d |
Biswas 2011 [24] | India | Bevacizumab and ranibizumab | 18 | 50/54d | 64.4/63.5d |
LUCAS 2015 [18] | Norway | Bevacizumab and ranibizumab | 24 | 213/218d | 62/78d |
BRAMD 2016 [19] | Netherlands | Bevacizumab and ranibizumab | 12 | 161/166d | 79/78d |
VIEW 1 [25] | United States and Canada | Aflibercept and ranibizumab | 24 | 911/304e | 78/78e |
VIEW 2 [25] | Europe, the Middle East, Asia-Pacific, and Latin America | Aflibercept and ranibizumab | 24 | 913/291e | 74/73e |